Genentech profits continue to soar
Operating revenues for the second quarter of 2005 of $1.53 billion represent a 35% increase on revenues of $1.12 billion for the same period in 2004. This has
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.